^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Legalon (silibinin)

Associations
Trials
Company:
Viatris
Drug class:
RNA polymerase inhibitor
Associations
Trials
19d
In Silico Discovery of a Novel PI3Kδ Inhibitor Incorporating 3,5,7-Trihydroxychroman-4-one Targeting Diffuse Large B-Cell Lymphoma. (PubMed, Int J Mol Sci)
The results of molecular dynamics indicated that Silibinin could stably bind to PI3Kδ. Silibinin was a structurally novel 3,5,7-trihydroxychroman-4-one PI3Kδ inhibitor, providing valuable information for the subsequent discovery of PI3Kδ inhibitors.
Journal
|
PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
|
Legalon (silibinin)
19d
Silibinin Suppresses Inflammatory Responses Induced by Exposure to Asian Sand Dust. (PubMed, Antioxidants (Basel))
Overall, silibinin treatment reduced the expression of p-p65NF-κB, COX-2, and p-p38 in response to ASD exposure, while increasing HO-1 expression both in vitro and in vivo. These findings suggest that silibinin mitigates pulmonary inflammation caused by ASD exposure by reducing inflammatory signaling and oxidative stress, indicating its potential as a therapeutic agent for ASD-induced pulmonary inflammation.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
Legalon (silibinin)
3ms
Herb-Nanoparticle Hybrid System for Improved Oral Delivery Efficiency to Alleviate Breast Cancer Lung Metastasis. (PubMed, Int J Nanomedicine)
Inspired by the unique chemical features of natural herbs, we propose an oral herb-nanoparticle hybrid system (HNS) formed through the self-binding of Platycodon grandiflorum-Curcuma zedoaria (HG), a herb pair/group used in clinical practice to treat breast cancer metastasis, to lipid-polymer nanoparticles (LPNs) loaded with silibinin...HNS provides an appealing system with multi-component binding of herbal medicine to facilitate both oral nanoparticle delivery efficiency and the alleviation of lung metastasis. This strategy may potentially help improve treatment for patients with breast cancer.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
Legalon (silibinin)
4ms
Silibinin Induces Both Apoptosis and Necroptosis with Potential Anti-tumor Efficacy in Lung Cancer. (PubMed, Anticancer Agents Med Chem)
This study helped clarify the anti-tumor mechanism of SiL against lung cancer, elucidating its role in dual induction of apoptosis and necroptosis. In particular, necroptosis blockade could switch cell death to apoptosis and increase the inhibitory effect of SiL. Our work provided an experimental basis for the research on cell death induced by SiL and revealed its possible applications for improving the management of lung cancer.
Journal
|
RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
|
Legalon (silibinin)
4ms
Synthesis, Characterization, and In-Vitro Evaluation of Silibinin-loaded PEGylated Niosomal Nanoparticles: Potential Anti-Cancer Effects on SW480 Colon Cancer Cells. (PubMed, Asian Pac J Cancer Prev)
The outcomes of this study indicate the high potential of PEGylated niosomal nanoparticles for encapsulation and delivery of silibinin to cancer cells, with no negative effects on normal cells.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein)
|
Legalon (silibinin)
4ms
Silibinin improved the function of T cells in peripheral blood mononuclear cells (PBMCs) co-cultured with U-87 MG cell line. (PubMed, Avicenna J Phytomed)
Interestingly, silibinin protected PBMCs against the U-87-induced suppression. Altogether, these results proposed the immunomodulatory potential of silibinin on T cells of PBMCs, as well as its partially protective effects on PBMCs against the suppression induced by U-87 MG cells.
Preclinical • Journal
|
IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1) • SOD3 (Superoxide dismutase 3)
|
Legalon (silibinin)
5ms
Codelivery of methotrexate and silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells. (PubMed, Biomed Mater)
In conclusion, the design and application of niosome to co-administer Sil and MTX can increase the drugs cytotoxicity, reduce their dose and improve anti-cancer potential by combating MDR. .
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
methotrexate • Legalon (silibinin)
5ms
The silibinin-loaded Zein-β cyclodextrin nano-carriers (SZBC-NCs) as a novel selective cancer cell drug delivery system in HT-29 cell line. (PubMed, Sci Rep)
Therefore, they can potentially be used as a safe efficient colon cancer treatment strategy. However, further in vivo experiments including animal cancer models have to be studied.
Preclinical • Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
Legalon (silibinin)
5ms
Silibinin, Synergistically Enhances Vinblastine-Mediated Apoptosis in Triple Negative Breast Cancer Cell Line: Involvement of Bcl2/Bax and Caspase-3 Pathway. (PubMed, Int J Hematol Oncol Stem Cell Res)
Significant upregulation of Bax (2.96-fold) and caspase-3 (3.46-fold) while Bcl-2 was downregulated by 2-fold. Findings established a preclinical rationale for the combination of silibinin and vinblastine. This combination produces synergistic effects in MDA-MB-231 cells by altering pro- and anti-apoptotic genes, which may reduce the toxicity and side effects of vinblastine.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
vinblastine • Legalon (silibinin)
6ms
The anticancer impact of folate-linked ZnO-decorated bovine serum albumin/silibinin nanoparticles on human pancreatic, breast, lung, and colon cancers. (PubMed, J Biomater Sci Polym Ed)
On the other hand, considering the powerful antioxidant activity of FZBS-NP, they have the potential to selectively induce apoptosis in human colon and breast cancer cells and protect normal types, which makes it an efficient safe anticancer compound. However, to verify the FZBS-NP anti-cancer efficiency further cancer and normal cell lines are required to measure several types of apoptotic gene expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • ANXA5 (Annexin A5)
|
Legalon (silibinin)
7ms
7-O-tyrosyl Silybin Derivatives as a Novel Set of Anti-Prostate Cancer Compounds. (PubMed, Antioxidants (Basel))
Additionally, Western blotting for apoptotic marker cleaved caspase-3 confirmed apoptosis induction by these silybin derivatives in PC-3 cells. These findings hold significant importance in the investigation of anticancer properties of silybin derivatives and strongly encourage swift investigation in pre-clinical models and clinical trials.
Journal
|
CASP3 (Caspase 3)
|
Legalon (silibinin)
8ms
The role of miR-133a in silibinin-mediated inhibition of the PI3K/AKT/mTOR pathway in MCF-7 breast carcinoma cells. (PubMed, Mol Biol Res Commun)
The findings enhance comprehension of silibinin's impact on PAM signaling and miR-133a expression, offering promise for targeted therapies in disrupting oncogenic pathways in MCF-7 breast cancer cells. This insight could advance breast cancer treatment strategies.
Journal
|
EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)
|
EGFR expression
|
Legalon (silibinin)
8ms
Nano-delivery of Silibinin Potentiate the Induction of Immunogenic Cell Death (ICD) in Melanoma Cells. (PubMed, Curr Pharm Biotechnol)
Our findings showed that the encapsulation of silibinin in polymeric nanocarriers can potentiate the effects of this drug on the induction of apoptosis and ICD in B16F10 melanoma cells.
Journal
|
CALR (Calreticulin) • ANXA5 (Annexin A5) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
Legalon (silibinin)
10ms
Silymarin and Inflammation: Food for Thoughts. (PubMed, Antioxidants (Basel))
Accumulating evidence indicates that silymarin (SM) and its main constituent silibinin/silybin (SB) have great potential as an anti-inflammation agent...At the same time, the anti-inflammatory action of SM/SB was confirmed in a number of in vivo models, including toxicity models, nonalcoholic fatty liver disease, ischemia/reperfusion models, stress-induced injuries, ageing and exercising models, wound healing and many other relevant model systems. It seems likely that the anti-inflammatory activities of SM/SB are key elements on the health-promoting properties of these phytochemicals.
Review • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4) • IL23A (Interleukin 23 Subunit Alpha) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4)
|
Legalon (silibinin)
11ms
Role of heat shock protein 70 in silibinin-induced apoptosis in bladder cancer. (PubMed, J Cancer)
Results from in vivo study demonstrated that silibinin suppressed the growth of bladder cancer xenografts, which was accompanied with the activation of caspase-3 and downregulation of HSF1 and Hsp70. Taken together, our data indicates that silibinin induces mitochondrial apoptosis via inhibiting HSF1/Hsp70 pathway and also suggests the therapeutic potential of silibinin in the treatment of bladder cancer.
Journal
|
CASP3 (Caspase 3) • CASP9 (Caspase 9) • APAF1 (Apoptotic peptidase activating factor 1) • HSF1 (Heat Shock Transcription Factor 1)
|
Legalon (silibinin)
11ms
Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors. (PubMed, Int J Mol Sci)
Other studies compare the effects of Montelukast and Zafirlukast (inhibitors of the cysteinyl leukotriene receptor, which is different from LTB4R/LTB4R2) on the MDA-MB-231 (TNBC) cell line, with high methylation and low expression levels of LTB4R...LY255283, Minocycline, Silibinin, Piceatannol, Mitiglinide, 1-Azakenpaullone, Carbetocin, and Pim-1-inhibitor-2 can be considered as candidates for the additional treatment of TNBC patients with tumors demonstrating LTB4R/LTB4R2 hypomethylation/upregulation. Finally, our results suggest that the epigenetic status of leukotriene B4 receptors is a novel, potential, predictive, and prognostic biomarker for TNBC. These findings might improve individualized therapy for TNBC patients by introducing new therapeutic adjuncts as anticancer agents.
Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset) • LTB4R2 (Leukotriene B4 Receptor 2)
|
Legalon (silibinin) • minocycline
12ms
The role of NFATc1 in the progression and metastasis of prostate cancer: A review on the molecular mechanisms and signaling pathways. (PubMed, Cell Biol Int)
Using Silibinin as a medicinal plant extract can inhibit the activity of osteoclasts related to prostate cancer by targeting NFATc...In this review, we will highlight the role of NFATc1 in the progression and metastasis of prostate cancer. Furthermore, we will summarize signaling pathways and molecular mechanism, through which NFATc1 regulates the process of prostate cancer.
Review • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
Legalon (silibinin)
1year
Silibinin: an inhibitor for a high-expressed BCL-2A1/BFL1 protein, linked with poor prognosis in breast cancer. (PubMed, J Biomol Struct Dyn)
Breast cancer (BC) accounts for 30% of all diagnosed cases of cancer in women and remains a leading cause of cancer-related deaths among women worldwide. Additionally, the compound is found to be better than Venetoclax and Nematoclax. We firmly believe in the compound CHEMBL9509 potency to halt BC's progression by inhibiting the BCL-2A1/BFL1 protein, increasing patients' survivability.Communicated by Ramaswamy H. Sarma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
Venclexta (venetoclax) • Legalon (silibinin)
1year
Silibinin Downregulates Types I and III Collagen Expression via Suppression of the mTOR Signaling Pathway. (PubMed, Int J Mol Sci)
Our findings suggest the potential of silibinin as a promising therapeutic agent for preventing and treating keloid scars. Further studies are warranted to explore the clinical application of silibinin in scar management.
Journal
|
Legalon (silibinin)
over1year
Silibinin alleviates ferroptosis of rat islet β cell INS-1 induced by the treatment with palmitic acid and high glucose through enhancing PINK1/parkin-mediated mitophagy. (PubMed, Arch Biochem Biophys)
By using the pharmacological stimulator and inhibitor of mitophagy, and si-RNA transfection to silence PINK1 expression, silibinin's protective effect against ferroptosis caused by PA and HG treatment was found to depend on mitophagy. Collectively, our current study reveals the new mechanisms for the protection of silibinin against the injury of INS-1 cells treated with PA and HG, elucidates the participation of ferroptosis in glucolipotoxicity, highlighting the involvement of mitophagy in defense against ferroptotic cell death.
Preclinical • Journal
|
GPX4 (Glutathione Peroxidase 4) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • PINK1 (PTEN Induced Kinase 1) • SLC2A4 (Solute Carrier Family 2 Member 4)
|
Legalon (silibinin)
over1year
Safety and efficacy of silibinin in patients with brain metastases after SRS: SUSTAIN trial (ESTRO 2023)
Radiological radionecrosis was detected in 3 pts (10%), who developed G1 neurological symptoms managed with low-dose dexamethasone. Toxicity proved manageable, consistent with the literature and limited to gastrointestinal effects. A larger sample and longer follow-up is needed to confirm our hypothesis.
Clinical
|
dexamethasone • Legalon (silibinin)
over1year
A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. (PubMed, Cancer Cell Int)
According to the findings, it was found that the co-administration of silymarin/silibinin alleviates the doxorubicin-induced cardiac adverse effects. Silymarin/silibinin exerts its cardioprotective effects via antioxidant, anti-inflammatory, anti-apoptotic activities, and other mechanisms.
Review • Journal
|
doxorubicin hydrochloride • Legalon (silibinin)
over1year
Silibinin Inhibits Cell Invasion through the Inhibition of MMPs, p-p38, and IL-1β in Human Fibrosarcoma Cells. (PubMed, Front Biosci (Landmark Ed))
These findings indicate that silibinin may have an inhibitory effect on the enzymes involved in invasion, hence it might influence the metastatic ability of tumor cells.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta)
|
Legalon (silibinin)
over1year
Core Structure-Activity Relationship Studies of 5,7,20-O-Trimethylsilybins in Prostate Cancer Cell Models. (PubMed, Pharmaceuticals (Basel))
The structure-activity relationships among the four different core structures (including flavanonol-type flavonolignan (silibinin), flavone-type flavonolignan (hydnocarpin D), chalcone-type flavonolignan, and taxifolin (a flavonolignan precursor) indicate that 5,7,20-O-trimethylsilybins are the most promising scaffold to selectively suppress AR-positive LNCaP prostate cancer cell proliferation. Further investigation on the antiproliferative potency of their optically enriched versions of the most promising 5,7,20-O-trimethylsilybins led to the conclusion that (10R,11R) derivatives (silybin A series) are more potent than (10S,11S) derivatives (silybin B series) in suppressing AR positive LNCaP cell proliferation.
Journal
|
AR (Androgen receptor)
|
AR positive • AR negative
|
Legalon (silibinin)
over1year
Effects of silibinin on apoptosis and insulin secretion in rat RINm5F pancreatic β-cells. (PubMed, Biotech Histochem)
Silibinin increased the expression of neurod1, mafa and glut2, but reduced pdx1 expression. Our findings suggest that silibinin might increase glucose sensitivity and insulin synthesis under glucotoxic conditions, which could be useful for diabetes treatment.
Preclinical • Journal
|
MAF (MAF BZIP Transcription Factor) • PDX1 (Pancreatic And Duodenal Homeobox 1) • NEUROD1 (Neuronal Differentiation 1)
|
Legalon (silibinin)
over1year
Effect of Silibinin on the Expression of Mir-20b, Bcl2L11, and Erbb2 in Breast Cancer Cell Lines. (PubMed, Mol Biotechnol)
Computational docking showed a strong interaction between SB/ MiR‑20b and SB/Erbb2. It can be concluded that SB had a strong anti-tumorigenic activity through BCL2L11upregulation and MiR‑20b down expression, maybe through targeting the PTEN and interacting with Erbb2, which resulted in apoptotic induction and cell cycle arrest.
Preclinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • BCL2L11 (BCL2 Like 11) • TYK2 (Tyrosine Kinase 2) • CASP9 (Caspase 9) • MIR20B (MicroRNA 20b)
|
HER-2 expression • BCL2 expression
|
Legalon (silibinin)
over1year
Anticancer Mechanism of Flavonoids on High-Grade Adult-Type Diffuse Gliomas. (PubMed, Nutrients)
This review discusses the anticancer mechanism of flavonoids (quercetin, rutin, chrysin, apigenin, naringenin, silibinin, EGCG, genistein, biochanin A and C3G) through targeting molecules associated with high-grade adult-type diffuse glioma cell proliferation, apoptosis, oxidative stress, cell cycle arrest, migration, invasion, autophagy and DNA repair. Moreover, the clinical relevance of flavonoid molecular targets in high-grade adult-type diffuse gliomas is discussed with comparison to small molecules inhibitors: ralimetinib, AMG232, marimastat, hydroxychloroquine and chloroquine. Despite the positive pre-clinical results, further investigations in clinical studies are warranted to substantiate the efficacy and safety of the use of flavonoids on high-grade adult-type diffuse glioma patients.
Review • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • MMP9 (Matrix metallopeptidase 9) • BECN1 (Beclin 1)
|
navtemadlin (KRT-232) • hydroxychloroquine • chloroquine phosphate • ralimetinib (LY 2228820)
over1year
SILIBININ, AN HSP90 INHIBITOR, ON HUMAN ACTH-SECRETING ADENOMAS. (PubMed, Neuroendocrinology)
Our findings indicate that silibinin can inhibit ACTH synthesis and secretion in individual human corticotroph adenomas and directly affects NR3C1 gene expression. These results reveal promising effects of this HSP90 inhibitor on human corticotroph adenomas and support an innovative target treatment for patients with Cushing's disease.
Journal
|
NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
|
Legalon (silibinin)
2years
Silibinin Radiosensitizes EGF Receptor-knockdown Prostate Cancer Cells by Attenuating DNA Repair Pathways. (PubMed, J Cancer Prev)
The pro-survival signaling proteins, phospho-extracellular signal-regulated kinases (ERK)1/2, phospho-Akt and phospho-STAT3 were decreased by silibinin in EGFR-deficient PCa cells. These findings suggest a novel mechanism of silibinin-induced radiosensitization of PCa cells by targeting DNA repair pathways, HR and NHEJ, and suppressing the pro-survival signaling pathways, ERK1/2, Akt and STAT3, in EGFR-knockdown PCa cells.
Journal
|
RAD51 (RAD51 Homolog A) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
Legalon (silibinin)
2years
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells. (PubMed, Int J Mol Sci)
Computational analyses and cell-free biochemical assays predicted a weak to moderate inhibitory activity of clinically relevant concentrations of silibinin against CYP3A4 when compared with recommended (rosuvastatin) and non-recommended (simvastatin) statins for lorlatinib-associated dyslipidemia. The elevated plasma cholesterol and triglyceride levels in lorlatinib-treated lung cancer patients might involve primary alterations in the hepatic accumulation of lipid intermediates. Silibinin could be clinically explored to reduce the undesirable hyperlipidemic activity of lorlatinib in lung cancer patients.
Journal
|
CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
Lorbrena (lorlatinib) • simvastatin • Legalon (silibinin)
2years
Targets for Renal Carcinoma Growth Control Identified by Screening FOXD1 Cell Proliferation Pathways. (PubMed, Cancers (Basel))
While silibinin reduced 3D growth in a subset of tumor replicas, FDI-6 reduced growth in all. This study identifies tractable pathways to target G2/M transition and inhibit ccRCC growth, demonstrates the applicability of these strategies across patient tumor replicas, and provides a platform for individualized patient testing of compounds that inhibit tumor growth.
Journal
|
FOXM1 (Forkhead Box M1) • FOXD1 (Forkhead Box D1)
|
Legalon (silibinin)
over2years
A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. (PubMed, Oxid Med Cell Longev)
Oxidative stress is often contributed to the progression of NAFLD, and hence, antioxidants such as silymarin, silybin, or silibinin, pentoxifylline, resveratrol, and vitamins A, C, and E are used in clinical trials against NAFLD. However, to date, none of these antioxidants have been used as a definite therapeutic agent in NAFLD patients. Further, these antioxidants should be studied in NAFLD patients with larger populations and multiple endpoints in the future.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
Legalon (silibinin)
over2years
Silibinin promotes melanogenesis through the PKA and p38 MAPK signaling pathways in melanoma cells. (PubMed, Biomed Res)
These results suggest that silibinin is an effective stimulator of melanogenesis through upregulation of the protein expression of melanogenic enzymes activated by the PKA and p38 pathways, leading to CREB phosphorylation and MITF expression. Therefore, silibinin may have potential for use in the treatment of hypopigmentation disorders.
Journal
|
MITF (Melanocyte Inducing Transcription Factor)
|
Legalon (silibinin)
over2years
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • SMAD2 (SMAD Family Member 2)
|
CDH1 expression • VIM expression
|
Legalon (silibinin)
over2years
Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation. (PubMed, Asian Pac J Cancer Prev)
Present preliminary study shows that co-incorporating Met, Sil, Fe3O4 into PLGA/PEG NPs might provide a more promising and safe treatment strategy for lung cancer.
Journal
|
LEP (Leptin)
|
metformin • Legalon (silibinin)
over2years
Chemopreventive Efficacy of Silibinin against Basal Cell Carcinoma Growth and Progression in UVB-irradiated Ptch +/- mice. (PubMed, Carcinogenesis)
Immunohistochemistry and immunofluorescence studies revealed that silibinin significantly decreased basal cell proliferation (Ki-67) and the expression of cytokeratins (14 and 15), and Hedgehog signaling mediators Smo and Gli1 in the BCC lesions. Together, our findings demonstrate strong potential of silibinin to be efficacious in preventing the growth and progression of UVB-induced BCC.
Preclinical • Journal
|
PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1)
|
Legalon (silibinin)
almost3years
BNIP3 contributes to silibinin-induced DNA double strand breaks in glioma cells via inhibition of mTOR. (PubMed, Biochem Biophys Res Commun)
Notably, silibinin-induced dephosphorylation of mTOR is also prevented when BNIP3 is knocked down. Given that activated mTOR could promote xCT expression and inhibit autophagic degradation of catalase, our data suggest that BNIP3 contributes to silibinin-induced DNA DSBs via improving intracellular ROS by inhibition of mTOR.
Journal
|
CAT (Catalase)
|
Legalon (silibinin)
almost3years
Journal
|
ER (Estrogen receptor)
|
doxorubicin hydrochloride • Legalon (silibinin)
almost3years
Synergistic anti-cancer effects of silibinin-etoposide combination against human breast carcinoma MCF-7 and MDA-MB-231 cell lines. (PubMed, Iran J Basic Med Sci)
Neither silibinin nor etoposide individually increased the level of P53 and P-P53 in MDA-MB-231 cells, but both of them individually and combined increased the level of P21. Since the silibinin-etoposide combination induces apoptosis in both cell lines with and without expression of p53, thus, it is suggested that this combination may be a successful therapeutic strategy for breast cancer regardless of P53 status.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • TP53 expression • BAX expression
|
etoposide IV • Legalon (silibinin)
almost3years
Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. (PubMed, J Evid Based Integr Med)
The 3 more important isomers are silybin (or silibinin), silydianin, and silychristin...This review deals with recent investigations to elucidate the molecular actions of this flavonoid in cancer, and to consider the possibility of repurposing it. Particular attention is dedicated to silymarin's dual role in cancer and to some controversies of its real effectiveness.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
HIF1A expression
|
Legalon (silibinin)
almost3years
Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells. (PubMed, Bioinformation)
Data shows that SSNPs have the potential to induce apoptosis in colorectal cancer cells. This provides insights for the further evaluation of SSNPs in fighting colon cancer.
Journal
|
TP53 (Tumor protein P53)
|
TP53 expression
|
Legalon (silibinin)